2,174
Views
9
CrossRef citations to date
0
Altmetric
Original article

Caregivers’ and physicians’ attitudes to rotigotine transdermal patch versus oral Parkinson’s disease medication: an observational study

, , , , , & show all
Pages 967-974 | Accepted 11 Mar 2015, Published online: 16 Mar 2015

References

  • Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011;26:399-406
  • Chaudhuri KR, Odin P, Antonini A, et al. Parkinson's disease: the non-motor issues. Parkinsonism Relat Disord 2011;17:717-23
  • Antonini A, Barone P, Marconi R, et al. The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. J Neurol 2012;259:2621-31
  • Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ. Quality of life and burden in caregivers for patients with Parkinson's disease: concepts, assessment and related factors. Expert Rev Pharmacoecon Outcomes Res 2012;12:221-30
  • Tse W, Frisina PG, Halbig TD, et al. The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism. J Am Med Dir Assoc 2008;9:670-5
  • van Rumund A, Weerkamp N, Tissingh G, et al. Perspectives on Parkinson Disease Care in Dutch Nursing Homes. J Am Med Dir Assoc 2014;15:732-7
  • Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatrics Soc 2000;48:938-42
  • Grosset D. Therapy adherence issues in Parkinson's disease. J Neurol Sci 2010;289:115-18
  • Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009;24:826-32
  • Fargel M, Grobe B, Oesterle E, et al. Treatment of Parkinson's disease: a survey of patients and neurologists. Clin Drug Investig 2007;27:207-18
  • Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson's disease. Mov Disord 2004;19:513-17
  • Elshoff JP, Braun M, Andreas JO, et al. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Therapeut 2012;34:966-78
  • Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22:2398-404
  • Jankovic J, Watts RL, Martin W, et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007;64:676-82
  • Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68:272-6
  • Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007;6:513-20
  • LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007;68:1262-7
  • Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011;26:90-9
  • European Medicines Agency. Neupro: EPAR Product Information. Summary of Product Characteristics. UCB Manufacturing Ireland Ltd, Ireland; first published 21 December 2009
  • Abetz L, Rofail D, Mertzanis P, et al. Alzheimer's disease treatment: assessing caregiver preferences for mode of treatment delivery. Adv Ther 2009;26:627-44
  • Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatr 2007;22:485-91
  • Martinez-Martin P, Forjaz MJ, Frades-Payo B, et al. Caregiver burden in Parkinson's disease. Mov Disord 2007;22:924-31; quiz 1060
  • Wüllner U, Kassubek J, Odin P, et al. Transdermal rotigotine for the perioperative management of Parkinson's disease. J Neural Transmission 2010;117:855-9
  • Cawello W, Ahrweiler S, Sulowicz W, et al. Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function. Br J Clin Pharmacol 2012;73:46-54
  • Korczyn AD, Reichmann H, Boroojerdi B, et al. Rotigotine transdermal system for perioperative administration. J Neural Transmission 2007;114:219-21
  • Wullner U, Fuchs G, Reketat N, et al. Requirements for Parkinson's disease pharmacotherapy from the patients' perspective: a questionnaire-based survey. Curr Med Res Opin 2012;28:1239-46
  • Adler G, Mueller B, Articus K. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions. Int J Clin Pract 2014;68:465-70
  • Schnitzler A, Leffers KW, Hack HJ. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease. Parkinsonism Relat Disord 2010;16:513-16

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.